Matthew J Bernett
Overview
Explore the profile of Matthew J Bernett including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
513
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yadav R, Schubbert S, Holder P, Chiang E, Kiabi N, Bogaert L, et al.
Front Pharmacol
. 2024 Jun;
15:1380000.
PMID: 38887559
Introduction: Interleukin 15 (IL-15) is a potential anticancer agent and numerous engineered IL-15 agonists are currently under clinical investigation. Selective targeting of IL-15 to specific lymphocytes may enhance therapeutic effects...
2.
Li J, Clark R, Slaga D, Avery K, Liu K, Schubbert S, et al.
Mol Cancer Ther
. 2024 May;
23(9):1305-1316.
PMID: 38739434
An insufficient quantity of functional T cells is a likely factor limiting the clinical activity of T-cell bispecific antibodies, especially in solid tumor indications. We hypothesized that XmAb24306 (efbalropendekin alfa),...
3.
Nolan-Stevaux O, Li C, Liang L, Zhan J, Estrada J, Osgood T, et al.
Cancer Discov
. 2023 Oct;
14(1):90-103.
PMID: 37861452
Significance: Immunotherapy in prostate cancer has met with limited success due to the immunosuppressive microenvironment and lack of tumor-specific targets. AMG 509 provides a targeted immunotherapy approach to engage a...
4.
Zuch de Zafra C, Fajardo F, Zhong W, Bernett M, Muchhal U, Moore G, et al.
Clin Cancer Res
. 2019 Mar;
25(13):3921-3933.
PMID: 30918018
Purpose: Despite advances in the treatment of multiple myeloma, new therapies are needed to induce more profound clinical responses. T-cell-redirected lysis triggered by bispecific antibodies recruiting T cells to cancer...
5.
Moore G, Bernett M, Rashid R, Pong E, Nguyen D, Jacinto J, et al.
Methods
. 2018 Oct;
154:38-50.
PMID: 30366098
Bispecific monoclonal antibodies can bind two protein targets simultaneously and enable therapeutic modalities inaccessible by traditional mAbs. Bispecific formats containing a heterodimeric Fc region are of particular interest, as a...
6.
Bernett M, Chu S, Leung I, Moore G, Lee S, Pong E, et al.
MAbs
. 2013 Apr;
5(3):384-96.
PMID: 23549103
The CTLA4-Ig fusion proteins abatacept and belatacept are clinically proven immunosuppressants used for rheumatoid arthritis and renal transplant, respectively. Given that both biologics are typically administered chronically by infusion, a...
7.
Chu S, Horton H, Pong E, Leung I, Chen H, Nguyen D, et al.
J Allergy Clin Immunol
. 2012 Jan;
129(4):1102-15.
PMID: 22257644
Background: Sequestration of IgE to prevent its binding to high-affinity IgE receptor FcεRI on basophils and mast cells is an effective therapy for allergic asthma. IgE production requires differentiation of...
8.
Tai Y, Horton H, Kong S, Pong E, Chen H, Cemerski S, et al.
Blood
. 2012 Jan;
119(9):2074-82.
PMID: 22246035
HM1.24, an immunologic target for multiple myeloma (MM) cells, has not been effectively targeted with therapeutic monoclonal antibodies (mAbs). In this study, we investigated in vitro and in vivo anti-MM...
9.
Horton H, Bernett M, Peipp M, Pong E, Karki S, Chu S, et al.
Blood
. 2010 Jul;
116(16):3004-12.
PMID: 20616215
CD40 is highly expressed on various B-lineage malignancies and represents an attractive immunotherapy target for neoplastic disease. Previous work showed that engineering the Fc domain of an antibody for increased...
10.
Bernett M, Karki S, Moore G, Leung I, Chen H, Pong E, et al.
J Mol Biol
. 2010 Jan;
396(5):1474-90.
PMID: 20045416
Fully human monoclonal antibodies (mAbs) derived from transgenic mice or human antibody libraries are the current state of the art for reducing the immunogenicity risk of antibody drugs. Here, we...